NEW YORK (GenomeWeb News) – Goldman Sachs has upgraded the stock of Agilent Technologies and Bruker, but downgraded Cepheid and Laboratory Corporation of America.

In a report released Sunday about the impending fiscal cliff as well as the global macroeconomic picture, analyst Isaac Ro upgraded the stocks of both Agilent and Bruker to a Buy rating from Neutral, but lowered Cepheid to Neutral from Buy and LabCorp to Sell from Neutral.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.